{"hands_on_practices": [{"introduction": "Histamine is a primary mediator of the immediate phase of acute inflammation, responsible for cardinal signs like swelling. The magnitude of this effect follows a predictable relationship with its concentration. This exercise [@problem_id:4340897] allows you to apply the Hill–Langmuir model, a cornerstone of pharmacology, to quantify how a change in histamine levels translates into a specific physiological response—increased vascular permeability. Understanding this quantitative link is crucial for appreciating how mediator concentrations directly dictate the severity of clinical signs.", "problem": "In acute inflammation, histamine released from mast cells binds Histamine H1 receptors (H1R) on postcapillary venular endothelium and increases permeability by contracting endothelial cells and opening intercellular junctions. Assume the following foundational principles: (i) receptor-mediated responses can be modeled by the Hill–Langmuir occupancy relation, in which fractional receptor occupancy is given by $$\\theta([H])=\\frac{[H]^{n}}{K_{d}^{n}+[H]^{n}},$$ where $[H]$ is the free histamine concentration, $K_{d}$ is the dissociation constant, and $n$ is the Hill coefficient capturing effective cooperativity of the integrated response; and (ii) when downstream transduction is effectively linear near the operating range, the physiological effect scales with occupancy as $$E([H])=E_{\\max}\\,\\theta([H]),$$ where $E_{\\max}$ is the maximum attainable increment in a dimensionless permeability index (normalized so that $E=0$ in the absence of histamine and $E=E_{\\max}$ at saturating histamine). For many G protein-coupled receptor systems under these assumptions, the half-maximal effective concentration $EC_{50}$ approximates $K_{d}$, so that $EC_{50}\\approx K_{d}$ is a well-tested operational parameter.\n\nA biopsy-based microdialysis study of an inflamed tissue records a baseline interstitial histamine concentration $[H]_{0}=0.50\\,\\mu\\text{M}$. A subsequent mast cell degranulation event doubles the local histamine to $[H]_{1}=1.00\\,\\mu\\text{M}$. For the venular permeability response in this tissue, take $E_{\\max}=1.50$ (dimensionless), $EC_{50}=0.75\\,\\mu\\text{M}$, and the effective Hill coefficient $n=2$.\n\nUsing the principles above, compute the fractional change in the permeability index relative to baseline, defined as $$\\Delta=\\frac{E([H]_{1})-E([H]_{0})}{E([H]_{0})}.$$ Express your final answer as a unitless decimal number, and round your answer to four significant figures.", "solution": "The problem statement is rigorously validated and found to be scientifically grounded, well-posed, objective, and internally consistent. It presents a standard biophysical modeling scenario based on the Hill–Langmuir equation, which is a cornerstone of quantitative pharmacology and receptor theory. The provided parameters for histamine concentration, $EC_{50}$, and Hill coefficient are within physiologically plausible ranges for receptor-mediated signaling. The problem is formalizable and requires a direct application of the given principles to compute a clear, uniquely defined quantity. Therefore, a complete solution is warranted.\n\nThe physiological effect, designated as the permeability index $E$, is a function of the histamine concentration $[H]$. It is given by the product of the maximum effect $E_{\\max}$ and the fractional receptor occupancy $\\theta([H])$:\n$$E([H]) = E_{\\max} \\, \\theta([H])$$\nThe fractional occupancy follows the Hill–Langmuir relation:\n$$\\theta([H]) = \\frac{[H]^{n}}{K_{d}^{n} + [H]^{n}}$$\nwhere $n$ is the Hill coefficient and $K_d$ is the dissociation constant. Combining these gives the full expression for the effect:\n$$E([H]) = E_{\\max} \\frac{[H]^{n}}{K_{d}^{n} + [H]^{n}}$$\nThe problem states that the half-maximal effective concentration $EC_{50}$ approximates the dissociation constant $K_d$. This is a common and reasonable operational assumption for systems where the biological response is linearly proportional to receptor occupancy. We therefore substitute $EC_{50}$ for $K_d$:\n$$E([H]) = E_{\\max} \\frac{[H]^{n}}{EC_{50}^{n} + [H]^{n}}$$\nWe are asked to compute the fractional change in the permeability index, $\\Delta$, as the histamine concentration increases from a baseline value of $[H]_{0} = 0.50\\,\\mu\\text{M}$ to a new value of $[H]_{1} = 1.00\\,\\mu\\text{M}$. The definition of $\\Delta$ is provided:\n$$\\Delta = \\frac{E([H]_{1}) - E([H]_{0})}{E([H]_{0})}$$\nThis can be rewritten as:\n$$\\Delta = \\frac{E([H]_{1})}{E([H]_{0})} - 1$$\nLet us now formulate the ratio $\\frac{E([H]_{1})}{E([H]_{0})}$. Using the expression for $E([H])$, we have:\n$$\\frac{E([H]_{1})}{E([H]_{0})} = \\frac{E_{\\max} \\frac{[H]_{1}^{n}}{EC_{50}^{n} + [H]_{1}^{n}}}{E_{\\max} \\frac{[H]_{0}^{n}}{EC_{50}^{n} + [H]_{0}^{n}}}$$\nThe term $E_{\\max}$ cancels, yielding:\n$$\\frac{E([H]_{1})}{E([H]_{0})} = \\frac{[H]_{1}^{n}}{[H]_{0}^{n}} \\cdot \\frac{EC_{50}^{n} + [H]_{0}^{n}}{EC_{50}^{n} + [H]_{1}^{n}}$$\nNow, we substitute the given numerical values into this expression:\n- Baseline histamine concentration: $[H]_{0} = 0.50\\,\\mu\\text{M}$\n- Post-degranulation histamine concentration: $[H]_{1} = 1.00\\,\\mu\\text{M}$\n- Half-maximal effective concentration: $EC_{50} = 0.75\\,\\mu\\text{M}$\n- Hill coefficient: $n = 2$\n\nSubstituting these values:\n$$\\frac{E([H]_{1})}{E([H]_{0})} = \\left(\\frac{1.00\\,\\mu\\text{M}}{0.50\\,\\mu\\text{M}}\\right)^{2} \\cdot \\frac{(0.75\\,\\mu\\text{M})^{2} + (0.50\\,\\mu\\text{M})^{2}}{(0.75\\,\\mu\\text{M})^{2} + (1.00\\,\\mu\\text{M})^{2}}$$\nThe units of concentration $\\mu\\text{M}$ cancel throughout the expression as expected, since the result must be dimensionless.\n$$\\frac{E([H]_{1})}{E([H]_{0})} = \\left(\\frac{1.00}{0.50}\\right)^{2} \\cdot \\frac{(0.75)^{2} + (0.50)^{2}}{(0.75)^{2} + (1.00)^{2}}$$\n$$= (2)^{2} \\cdot \\frac{0.5625 + 0.25}{0.5625 + 1.00}$$\n$$= 4 \\cdot \\frac{0.8125}{1.5625}$$\nTo avoid rounding errors, it is prudent to work with exact fractions. Let $EC_{50} = 3/4$, $[H]_0 = 1/2$, and $[H]_1 = 1$.\n$$\\frac{E([H]_{1})}{E([H]_{0})} = \\left(\\frac{1}{1/2}\\right)^{2} \\cdot \\frac{(3/4)^{2} + (1/2)^{2}}{(3/4)^{2} + (1)^{2}} = (2)^{2} \\cdot \\frac{9/16 + 1/4}{9/16 + 1} = 4 \\cdot \\frac{9/16 + 4/16}{9/16 + 16/16} = 4 \\cdot \\frac{13/16}{25/16} = 4 \\cdot \\frac{13}{25} = \\frac{52}{25}$$\nConverting the fraction to a decimal gives:\n$$\\frac{E([H]_{1})}{E([H]_{0})} = 2.08$$\nFinally, we compute $\\Delta$:\n$$\\Delta = \\frac{E([H]_{1})}{E([H]_{0})} - 1 = 2.08 - 1 = 1.08$$\nThe problem requires the answer to be rounded to four significant figures. The exact result $1.08$ has three significant figures. To express this with four, we must append a zero.\n$$\\Delta = 1.080$$\nThis represents a $108.0\\%$ increase in the vascular permeability index relative to its baseline value.", "answer": "$$\\boxed{1.080}$$", "id": "4340897"}, {"introduction": "Nonsteroidal anti-inflammatory drugs (NSAIDs) are a mainstay of therapy, but their clinical profiles vary based on which enzymes they target. This practice explores the competitive kinetics of two key enzymes, COX-1 and COX-2, which both process arachidonic acid but serve different physiological and pathological roles. By applying the principles of Michaelis-Menten kinetics and competitive inhibition [@problem_id:4340926], you will gain a quantitative understanding of drug selectivity, a concept that explains why different NSAIDs have distinct therapeutic benefits and side effect profiles.", "problem": "Arachidonic acid (AA) is converted to prostaglandin intermediates by the enzymes cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). Consider a cell in which both isoforms operate on the same substrate pool. Let the total flux through each isoform be the steady-state rate of product formation, which under the quasi-steady-state approximation equals the catalytic turnover of the enzyme–substrate complex. Use the following baseline parameters: for cyclooxygenase-1 (COX-1), $V_{max,1} = 120\\ \\mathrm{nmol\\,min^{-1}}$ and $K_{m,1} = 4\\ \\mathrm{\\mu M}$; for cyclooxygenase-2 (COX-2), $V_{max,2} = 150\\ \\mathrm{nmol\\,min^{-1}}$ and $K_{m,2} = 8\\ \\mathrm{\\mu M}$. The substrate concentration is $[AA] = 10\\ \\mathrm{\\mu M}$.\n\nNow introduce a Nonsteroidal Anti-Inflammatory Drug (NSAID), assumed to be a reversible competitive inhibitor with respect to AA for both isoforms, present at concentration $[I] = 5\\ \\mathrm{\\mu M}$. The inhibitor has different dissociation constants for the isoforms: $K_{i,1} = 1\\ \\mathrm{\\mu M}$ for COX-1 and $K_{i,2} = 10\\ \\mathrm{\\mu M}$ for COX-2.\n\nStarting from the fundamental scheme for enzyme catalysis $E + S \\rightleftharpoons ES \\rightarrow E + P$, and employing the quasi-steady-state approximation for $[ES]$, derive the expressions for the steady-state fluxes through COX-1 and COX-2 at baseline, and the modified fluxes in the presence of a reversible competitive inhibitor. Use these expressions to compute the baseline flux ratio $r_{b} = \\frac{v_{2}}{v_{1}}$ and the post-NSAID flux ratio $r_{a} = \\frac{v_{2}'}{v_{1}'}$, where the prime denotes inhibited conditions. Finally, compute the fold-change $F = \\frac{r_{a}}{r_{b}}$. Express $F$ as a dimensionless decimal and round your answer to three significant figures.", "solution": "The problem is evaluated as scientifically grounded, well-posed, objective, and complete. All necessary parameters are provided, and the question is based on fundamental principles of enzyme kinetics. Therefore, a full solution is warranted.\n\nThe problem requires the derivation of the rate equations for enzyme catalysis under baseline and competitive inhibition conditions, followed by the calculation of reaction flux ratios.\n\n**1. Derivation of the Steady-State Flux Equations**\n\nThe fundamental reaction scheme for a single-substrate enzyme is:\n$$ E + S \\underset{k_{-1}}{\\stackrel{k_1}{\\rightleftharpoons}} ES \\stackrel{k_2}{\\rightarrow} E + P $$\nwhere $E$ is the enzyme, $S$ is the substrate, $ES$ is the enzyme-substrate complex, and $P$ is the product. The rate constants for each step are $k_1$, $k_{-1}$, and $k_2$.\n\n**a. Baseline Flux (Michaelis-Menten Equation)**\n\nThe flux, $v$, is the rate of product formation:\n$$ v = \\frac{d[P]}{dt} = k_2 [ES] $$\nUsing the quasi-steady-state approximation (QSSA), we assume the concentration of the $ES$ complex is constant, i.e., $\\frac{d[ES]}{dt} = 0$. The rate of formation of $ES$ equals its rate of breakdown:\n$$ k_1 [E][S] = (k_{-1} + k_2) [ES] $$\nThe total enzyme concentration $[E]_0$ is the sum of free enzyme $[E]$ and complexed enzyme $[ES]$:\n$$ [E]_0 = [E] + [ES] \\implies [E] = [E]_0 - [ES] $$\nSubstituting $[E]$ into the steady-state equation:\n$$ k_1 ([E]_0 - [ES])[S] = (k_{-1} + k_2) [ES] $$\nRearranging to solve for $[ES]$:\n$$ k_1 [E]_0 [S] - k_1 [ES][S] = (k_{-1} + k_2) [ES] $$\n$$ k_1 [E]_0 [S] = (k_1 [S] + k_{-1} + k_2) [ES] $$\n$$ [ES] = \\frac{k_1 [E]_0 [S]}{k_1 [S] + k_{-1} + k_2} $$\nDividing the numerator and denominator by $k_1$:\n$$ [ES] = \\frac{[E]_0 [S]}{[S] + \\frac{k_{-1} + k_2}{k_1}} $$\nWe define the Michaelis constant, $K_m$, as $K_m = \\frac{k_{-1} + k_2}{k_1}$. The equation for $[ES]$ becomes:\n$$ [ES] = \\frac{[E]_0 [S]}{K_m + [S]} $$\nSubstituting this into the expression for the flux $v$:\n$$ v = k_2 [ES] = \\frac{k_2 [E]_0 [S]}{K_m + [S]} $$\nThe maximum flux, $V_{max}$, is achieved when the enzyme is saturated with substrate ($[ES] = [E]_0$), so $V_{max} = k_2 [E]_0$. This gives the final Michaelis-Menten equation for the baseline flux:\n$$ v = \\frac{V_{max} [S]}{K_m + [S]} $$\n\n**b. Flux in the Presence of a Competitive Inhibitor**\n\nA reversible competitive inhibitor, $I$, binds only to the free enzyme, forming an inactive $EI$ complex:\n$$ E + I \\rightleftharpoons EI $$\nThe dissociation constant for this equilibrium is $K_i = \\frac{[E][I]}{[EI]}$.\nThe total enzyme concentration is now distributed among three species:\n$$ [E]_0 = [E] + [ES] + [EI] $$\nFrom the inhibitor equilibrium, we have $[EI] = \\frac{[E][I]}{K_i}$. Substituting this into the mass balance:\n$$ [E]_0 = [E] \\left(1 + \\frac{[I]}{K_i}\\right) + [ES] $$\nThe QSSA for $[ES]$ remains unchanged: $k_1 [E][S] = (k_{-1} + k_2) [ES]$, which gives $[E] = \\frac{K_m}{[S]}[ES]$.\nSubstituting this expression for $[E]$ into the mass balance equation:\n$$ [E]_0 = \\frac{K_m}{[S]}[ES] \\left(1 + \\frac{[I]}{K_i}\\right) + [ES] $$\n$$ [E]_0 = [ES] \\left[ \\frac{K_m}{[S]} \\left(1 + \\frac{[I]}{K_i}\\right) + 1 \\right] $$\n$$ [E]_0 = [ES] \\frac{K_m \\left(1 + \\frac{[I]}{K_i}\\right) + [S]}{[S]} $$\nSolving for $[ES]$:\n$$ [ES] = \\frac{[E]_0 [S]}{K_m \\left(1 + \\frac{[I]}{K_i}\\right) + [S]} $$\nThe inhibited flux, $v'$, is $v' = k_2 [ES]$. Substituting the expression for $[ES]$ and using $V_{max} = k_2 [E]_0$:\n$$ v' = \\frac{V_{max} [S]}{K_m \\left(1 + \\frac{[I]}{K_i}\\right) + [S]} $$\nThis is the expression for the flux in the presence of a reversible competitive inhibitor.\n\n**2. Calculation of Fluxes and Ratios**\n\nThe given parameters are:\nSubstrate concentration: $[S] = [AA] = 10\\ \\mathrm{\\mu M}$.\nInhibitor concentration: $[I] = 5\\ \\mathrm{\\mu M}$.\nCOX-1: $V_{max,1} = 120\\ \\mathrm{nmol\\,min^{-1}}$, $K_{m,1} = 4\\ \\mathrm{\\mu M}$, $K_{i,1} = 1\\ \\mathrm{\\mu M}$.\nCOX-2: $V_{max,2} = 150\\ \\mathrm{nmol\\,min^{-1}}$, $K_{m,2} = 8\\ \\mathrm{\\mu M}$, $K_{i,2} = 10\\ \\mathrm{\\mu M}$.\n\n**a. Baseline Fluxes ($v_1$, $v_2$) and Ratio ($r_b$)**\n\nThe baseline flux for COX-1 is:\n$$ v_1 = \\frac{V_{max,1} [S]}{K_{m,1} + [S]} = \\frac{120 \\times 10}{4 + 10} = \\frac{1200}{14} = \\frac{600}{7}\\ \\mathrm{nmol\\,min^{-1}} $$\nThe baseline flux for COX-2 is:\n$$ v_2 = \\frac{V_{max,2} [S]}{K_{m,2} + [S]} = \\frac{150 \\times 10}{8 + 10} = \\frac{1500}{18} = \\frac{250}{3}\\ \\mathrm{nmol\\,min^{-1}} $$\nThe baseline flux ratio is:\n$$ r_b = \\frac{v_2}{v_1} = \\frac{250/3}{600/7} = \\frac{250}{3} \\times \\frac{7}{600} = \\frac{25 \\times 7}{3 \\times 60} = \\frac{35}{36} $$\n\n**b. Post-NSAID Fluxes ($v_1'$, $v_2'$) and Ratio ($r_a$)**\n\nFirst, we calculate the inhibition factor $\\alpha = \\left(1 + \\frac{[I]}{K_i}\\right)$ for each isoform.\nFor COX-1:\n$$ \\alpha_1 = 1 + \\frac{[I]}{K_{i,1}} = 1 + \\frac{5}{1} = 6 $$\nFor COX-2:\n$$ \\alpha_2 = 1 + \\frac{[I]}{K_{i,2}} = 1 + \\frac{5}{10} = 1.5 $$\nThe inhibited flux for COX-1 is:\n$$ v_1' = \\frac{V_{max,1} [S]}{K_{m,1}\\alpha_1 + [S]} = \\frac{120 \\times 10}{4 \\times 6 + 10} = \\frac{1200}{24 + 10} = \\frac{1200}{34} = \\frac{600}{17}\\ \\mathrm{nmol\\,min^{-1}} $$\nThe inhibited flux for COX-2 is:\n$$ v_2' = \\frac{V_{max,2} [S]}{K_{m,2}\\alpha_2 + [S]} = \\frac{150 \\times 10}{8 \\times 1.5 + 10} = \\frac{1500}{12 + 10} = \\frac{1500}{22} = \\frac{750}{11}\\ \\mathrm{nmol\\,min^{-1}} $$\nThe post-NSAID flux ratio is:\n$$ r_a = \\frac{v_2'}{v_1'} = \\frac{750/11}{600/17} = \\frac{750}{11} \\times \\frac{17}{600} = \\frac{75 \\times 17}{11 \\times 60} = \\frac{5 \\times 17}{11 \\times 4} = \\frac{85}{44} $$\n\n**c. Fold-Change in Flux Ratio ($F$)**\n\nThe fold-change $F$ is the ratio of the post-NSAID flux ratio to the baseline flux ratio:\n$$ F = \\frac{r_a}{r_b} = \\frac{85/44}{35/36} = \\frac{85}{44} \\times \\frac{36}{35} $$\nSimplifying the fraction:\n$$ F = \\frac{(5 \\times 17)}{(4 \\times 11)} \\times \\frac{(4 \\times 9)}{(5 \\times 7)} = \\frac{17 \\times 9}{11 \\times 7} = \\frac{153}{77} $$\nTo obtain the final decimal value, we perform the division:\n$$ F = \\frac{153}{77} \\approx 1.9870129... $$\nRounding to three significant figures, we get:\n$$ F \\approx 1.99 $$\nThis result indicates that the inhibitor is selective for COX-1, causing the flux ratio of COX-2 to COX-1 to approximately double.", "answer": "$$\n\\boxed{1.99}\n$$", "id": "4340926"}, {"introduction": "Corticosteroids are among the most potent anti-inflammatory drugs because they don't just block a single pathway, but reprogram the cell's inflammatory response at a fundamental level. This advanced exercise [@problem_id:4340848] guides you through building a systems-level model based on the central dogma of molecular biology. You will simulate how corticosteroids suppress inflammation by altering the gene expression of multiple key proteins, including COX-2 and iNOS, providing a powerful illustration of therapeutic intervention at the transcriptional level.", "problem": "An inflamed tissue produces prostaglandins, nitric oxide, and pro-inflammatory cytokines primarily via Cyclooxygenase-2 (COX-2), inducible Nitric Oxide Synthase (iNOS), and a cytokine gene cluster, respectively. Build a quantitative steady-state model for mediator concentrations using the following foundational principles:\n\n- Central dogma with first-order turnover: messenger ribonucleic acid (mRNA) for each gene is produced by transcription and degraded with a first-order rate; protein is produced by translation from mRNA and degraded with a first-order rate. Assume steady state so that production equals loss for each molecular species.\n- Receptor occupancy: a corticosteroid at concentration $D$ binds its intracellular receptor with dissociation constant $K_D$, giving fractional occupancy $f(D) = \\dfrac{D}{K_D + D}$.\n- Transrepression of transcription: for each gene $i \\in \\{\\mathrm{COX}, \\mathrm{iNOS}, \\mathrm{Cyt}\\}$, corticosteroid occupancy reduces the baseline transcription rate $k_{\\mathrm{tx},i}^{0}$ by a factor proportional to $f(D)$ with gene-specific sensitivity $\\alpha_i \\in (0,1)$, so that the drug-modified transcription rate is $k_{\\mathrm{tx},i}(D) = k_{\\mathrm{tx},i}^{0}\\big(1 - \\alpha_i f(D)\\big)$.\n- Enzyme-proportional mediator formation and first-order clearance: at steady state, each mediator concentration equals its formation rate (linear in the cognate enzyme abundance) divided by its first-order clearance rate.\n\nParameter values are as follows (units are provided for clarity; mediator concentrations are to be reported in nanomolar, nM):\n\n- Corticosteroid and receptor binding: $D = 50\\ \\mathrm{nM}$, $K_D = 20\\ \\mathrm{nM}$.\n- Gene-specific parameters:\n  - COX-2 (Cyclooxygenase-2): $k_{\\mathrm{tx},\\mathrm{COX}}^{0} = 20$ mRNA h$^{-1}$, $\\delta_{m,\\mathrm{COX}} = 0.5\\ \\mathrm{h}^{-1}$, $k_{\\mathrm{tl},\\mathrm{COX}} = 2$ protein mRNA$^{-1}$ h$^{-1}$, $\\delta_{p,\\mathrm{COX}} = 0.2\\ \\mathrm{h}^{-1}$, $\\alpha_{\\mathrm{COX}} = 0.8$.\n  - iNOS (inducible Nitric Oxide Synthase): $k_{\\mathrm{tx},\\mathrm{iNOS}}^{0} = 15$ mRNA h$^{-1}$, $\\delta_{m,\\mathrm{iNOS}} = 0.3\\ \\mathrm{h}^{-1}$, $k_{\\mathrm{tl},\\mathrm{iNOS}} = 2$ protein mRNA$^{-1}$ h$^{-1}$, $\\delta_{p,\\mathrm{iNOS}} = 0.1\\ \\mathrm{h}^{-1}$, $\\alpha_{\\mathrm{iNOS}} = 0.7$.\n  - Cytokine cluster: $k_{\\mathrm{tx},\\mathrm{Cyt}}^{0} = 25$ mRNA h$^{-1}$, $\\delta_{m,\\mathrm{Cyt}} = 1.0\\ \\mathrm{h}^{-1}$, $k_{\\mathrm{tl},\\mathrm{Cyt}} = 2$ protein mRNA$^{-1}$ h$^{-1}$, $\\delta_{p,\\mathrm{Cyt}} = 0.5\\ \\mathrm{h}^{-1}$, $\\alpha_{\\mathrm{Cyt}} = 0.9$.\n- Mediator formation proportionality constants and clearances:\n  - Prostaglandins from COX-2: $k_{p,\\mathrm{PG}} = 0.02\\ \\mathrm{nM\\,h^{-1}\\,enzyme^{-1}}$, $\\gamma_{\\mathrm{PG}} = 0.1\\ \\mathrm{h}^{-1}$.\n  - Nitric oxide from iNOS: $k_{p,\\mathrm{NO}} = 0.01\\ \\mathrm{nM\\,h^{-1}\\,enzyme^{-1}}$, $\\gamma_{\\mathrm{NO}} = 0.2\\ \\mathrm{h}^{-1}$.\n  - Cytokines from the cytokine cluster: $k_{p,\\mathrm{C}} = 0.03\\ \\mathrm{nM\\,h^{-1}\\,enzyme^{-1}}$, $\\gamma_{\\mathrm{C}} = 0.3\\ \\mathrm{h}^{-1}$.\n\nUsing only the principles above, derive an expression for the fold-change in the total pro-inflammatory mediator burden, defined as the ratio\n$$F \\equiv \\dfrac{[\\mathrm{PG}]_{D} + [\\mathrm{NO}]_{D} + [\\mathrm{C}]_{D}}{[\\mathrm{PG}]_{0} + [\\mathrm{NO}]_{0} + [\\mathrm{C}]_{0}},$$\nwhere $[\\cdot]_{0}$ denotes the steady-state concentration at baseline (no drug) and $[\\cdot]_{D}$ denotes the steady-state concentration at drug concentration $D$.\n\nCompute $F$ using the parameter values provided. Express the final fold-change as a pure number (unitless), rounded to three significant figures.", "solution": "The problem is to construct a quantitative model for the concentrations of three inflammatory mediators and to calculate the fold-change in the total mediator burden upon administration of a corticosteroid. The solution requires a step-by-step derivation based on the provided principles.\n\nFirst, we establish a general model for the steady-state abundance of an enzyme (protein), denoted $p_i$, corresponding to gene $i$. Let $m_i$ be the abundance of the mRNA for gene $i$. According to the central dogma principle with first-order turnover, the dynamic equations for $m_i$ and $p_i$ are:\n$$ \\frac{dm_i}{dt} = k_{\\mathrm{tx},i}(D) - \\delta_{m,i} m_i $$\n$$ \\frac{dp_i}{dt} = k_{\\mathrm{tl},i} m_i - \\delta_{p,i} p_i $$\nwhere $k_{\\mathrm{tx},i}(D)$ is the drug-dependent transcription rate, $\\delta_{m,i}$ is the mRNA degradation rate constant, $k_{\\mathrm{tl},i}$ is the translation rate constant, and $\\delta_{p,i}$ is the protein degradation rate constant.\n\nAt steady state, the time derivatives are zero. From the mRNA equation, we find the steady-state mRNA abundance, $m_{i,\\mathrm{ss}}$:\n$$ 0 = k_{\\mathrm{tx},i}(D) - \\delta_{m,i} m_{i,\\mathrm{ss}} \\implies m_{i,\\mathrm{ss}} = \\frac{k_{\\mathrm{tx},i}(D)}{\\delta_{m,i}} $$\nSubstituting this into the steady-state protein equation:\n$$ 0 = k_{\\mathrm{tl},i} m_{i,\\mathrm{ss}} - \\delta_{p,i} p_{i,\\mathrm{ss}} \\implies p_{i,\\mathrm{ss}} = \\frac{k_{\\mathrm{tl},i} m_{i,\\mathrm{ss}}}{\\delta_{p,i}} $$\nCombining these gives the steady-state protein abundance as a function of the transcription rate:\n$$ p_{i,\\mathrm{ss}}(D) = \\frac{k_{\\mathrm{tl},i}}{\\delta_{p,i}} \\left( \\frac{k_{\\mathrm{tx},i}(D)}{\\delta_{m,i}} \\right) = \\frac{k_{\\mathrm{tl},i} k_{\\mathrm{tx},i}(D)}{\\delta_{m,i} \\delta_{p,i}} $$\nThe problem defines the drug-dependent transcription rate as $k_{\\mathrm{tx},i}(D) = k_{\\mathrm{tx},i}^{0}\\big(1 - \\alpha_i f(D)\\big)$, where $f(D) = \\frac{D}{K_D + D}$. Substituting this into the expression for $p_{i,\\mathrm{ss}}(D)$:\n$$ p_{i,\\mathrm{ss}}(D) = \\frac{k_{\\mathrm{tl},i} k_{\\mathrm{tx},i}^{0} \\big(1 - \\alpha_i f(D)\\big)}{\\delta_{m,i} \\delta_{p,i}} $$\n\nNext, we model the steady-state concentration of a mediator, $[\\mathrm{M}_i]$, produced by the enzyme $p_i$. The formation rate is $k_{p,i} p_{i,\\mathrm{ss}}(D)$ and the clearance rate is $\\gamma_i [\\mathrm{M}_i]$. At steady state, these rates are equal:\n$$ k_{p,i} p_{i,\\mathrm{ss}}(D) = \\gamma_i [\\mathrm{M}_i]_D $$\nwhere $[\\mathrm{M}_i]_D$ denotes the steady-state mediator concentration at drug concentration $D$. Solving for $[\\mathrm{M}_i]_D$:\n$$ [\\mathrm{M}_i]_D = \\frac{k_{p,i} p_{i,\\mathrm{ss}}(D)}{\\gamma_i} $$\nSubstituting the expression for $p_{i,\\mathrm{ss}}(D)$:\n$$ [\\mathrm{M}_i]_D = \\frac{k_{p,i}}{\\gamma_i} \\left( \\frac{k_{\\mathrm{tl},i} k_{\\mathrm{tx},i}^{0} \\big(1 - \\alpha_i f(D)\\big)}{\\delta_{m,i} \\delta_{p,i}} \\right) $$\n\nAt baseline (no drug), $D=0$, which implies $f(0)=0$. The baseline concentration $[\\mathrm{M}_i]_0$ is therefore:\n$$ [\\mathrm{M}_i]_0 = \\frac{k_{p,i} k_{\\mathrm{tl},i} k_{\\mathrm{tx},i}^{0}}{\\gamma_i \\delta_{m,i} \\delta_{p,i}} $$\nWe can write $[\\mathrm{M}_i]_D$ in terms of $[\\mathrm{M}_i]_0$:\n$$ [\\mathrm{M}_i]_D = [\\mathrm{M}_i]_0 \\big(1 - \\alpha_i f(D)\\big) $$\n\nThe problem requires us to calculate the fold-change $F$:\n$$ F = \\dfrac{[\\mathrm{PG}]_{D} + [\\mathrm{NO}]_{D} + [\\mathrm{C}]_{D}}{[\\mathrm{PG}]_{0} + [\\mathrm{NO}]_{0} + [\\mathrm{C}]_{0}} $$\nTo do this, we first compute the numerical values for the fractional occupancy and the baseline concentrations of each mediator.\n\nThe fractional occupancy $f(D)$ with $D=50\\ \\mathrm{nM}$ and $K_D = 20\\ \\mathrm{nM}$ is:\n$$ f(D) = \\frac{50}{20 + 50} = \\frac{50}{70} = \\frac{5}{7} $$\n\nNow, calculate the baseline concentrations $[\\mathrm{M}_i]_0$ for each mediator.\nFor Prostaglandins (PG), produced by COX-2:\n$$ [\\mathrm{PG}]_0 = \\frac{k_{p,\\mathrm{PG}} k_{\\mathrm{tl},\\mathrm{COX}} k_{\\mathrm{tx},\\mathrm{COX}}^{0}}{\\gamma_{\\mathrm{PG}} \\delta_{m,\\mathrm{COX}} \\delta_{p,\\mathrm{COX}}} = \\frac{(0.02)(2)(20)}{(0.1)(0.5)(0.2)} = \\frac{0.8}{0.01} = 80\\ \\mathrm{nM} $$\nFor Nitric Oxide (NO), produced by iNOS:\n$$ [\\mathrm{NO}]_0 = \\frac{k_{p,\\mathrm{NO}} k_{\\mathrm{tl},\\mathrm{iNOS}} k_{\\mathrm{tx},\\mathrm{iNOS}}^{0}}{\\gamma_{\\mathrm{NO}} \\delta_{m,\\mathrm{iNOS}} \\delta_{p,\\mathrm{iNOS}}} = \\frac{(0.01)(2)(15)}{(0.2)(0.3)(0.1)} = \\frac{0.3}{0.006} = 50\\ \\mathrm{nM} $$\nFor Cytokines (C), produced by the cytokine cluster:\n$$ [\\mathrm{C}]_0 = \\frac{k_{p,\\mathrm{C}} k_{\\mathrm{tl},\\mathrm{Cyt}} k_{\\mathrm{tx},\\mathrm{Cyt}}^{0}}{\\gamma_{\\mathrm{C}} \\delta_{m,\\mathrm{Cyt}} \\delta_{p,\\mathrm{Cyt}}} = \\frac{(0.03)(2)(25)}{(0.3)(1.0)(0.5)} = \\frac{1.5}{0.15} = 10\\ \\mathrm{nM} $$\n\nThe total baseline mediator burden is the sum:\n$$ [\\mathrm{PG}]_0 + [\\mathrm{NO}]_0 + [\\mathrm{C}]_0 = 80 + 50 + 10 = 140\\ \\mathrm{nM} $$\n\nNext, we calculate the drug-treated steady-state concentrations $[\\mathrm{M}_i]_D$:\nFor Prostaglandins:\n$$ [\\mathrm{PG}]_D = [\\mathrm{PG}]_0 (1 - \\alpha_{\\mathrm{COX}} f(D)) = 80 \\left(1 - 0.8 \\cdot \\frac{5}{7}\\right) = 80 \\left(1 - \\frac{4}{7}\\right) = 80 \\left(\\frac{3}{7}\\right) = \\frac{240}{7}\\ \\mathrm{nM} $$\nFor Nitric Oxide:\n$$ [\\mathrm{NO}]_D = [\\mathrm{NO}]_0 (1 - \\alpha_{\\mathrm{iNOS}} f(D)) = 50 \\left(1 - 0.7 \\cdot \\frac{5}{7}\\right) = 50 (1 - 0.5) = 25\\ \\mathrm{nM} $$\nFor Cytokines:\n$$ [\\mathrm{C}]_D = [\\mathrm{C}]_0 (1 - \\alpha_{\\mathrm{Cyt}} f(D)) = 10 \\left(1 - 0.9 \\cdot \\frac{5}{7}\\right) = 10 \\left(1 - \\frac{4.5}{7}\\right) = 10 \\left(\\frac{2.5}{7}\\right) = \\frac{25}{7}\\ \\mathrm{nM} $$\n\nThe total drug-treated mediator burden is the sum:\n$$ [\\mathrm{PG}]_D + [\\mathrm{NO}]_D + [\\mathrm{C}]_D = \\frac{240}{7} + 25 + \\frac{25}{7} = \\frac{240}{7} + \\frac{175}{7} + \\frac{25}{7} = \\frac{240 + 175 + 25}{7} = \\frac{440}{7}\\ \\mathrm{nM} $$\n\nFinally, we compute the fold-change $F$:\n$$ F = \\frac{\\frac{440}{7}}{140} = \\frac{440}{7 \\cdot 140} = \\frac{44}{7 \\cdot 14} = \\frac{22}{7 \\cdot 7} = \\frac{22}{49} $$\nTo obtain the required numerical answer, we perform the division and round to three significant figures:\n$$ F = \\frac{22}{49} \\approx 0.44897959... $$\nRounding to three significant figures gives $F \\approx 0.449$.", "answer": "$$\\boxed{0.449}$$", "id": "4340848"}]}